| Biomarker ID | 686 |
| PMID | 21765474 |
| Year | 2012 |
| Biomarker | miR-96; miR-182; miR-32; miR-221; miR-25; miR-93; miR-182*; miR-106b; miR-183; miR-153; miR-602; miR-455-5p; miR-205 miR-183*; miR-425; miR-375; miR-193b; miR-30e*; miR-95; miR-378; miR-455-3p; miR-133a; miR-873; miR-222; miR-21; miR-142-3p; miR-575 ;miR-130b; miR-339-3p; miR-149; miR-338-3p; miR-19a; miR-148a; miR-146b-5p; miR-125a-5p; miR-27b; miR-10b*; miR-141; miR-7; miR-505; miR-30c-1*; miR-145*; miR-145; miR-125b; miR-99a; miR-378*; miR-583; miR-221*; miR-20a; miR-124; miR-103; miR-542-5p; miR-193b*; miR-941 |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Differentially Expressed (Fold Change): [miR-96 (2.12 fold); miR-182 (2.02 fold); miR-32 (2.01 fold); miR-221 (2.27 fold); miR-25 (1.53 fold); miR-93 (1.61 fold); miR-182* (2.25 fold); miR-106b (1.56 fold); miR-183 (2.18 fold); miR-153 (2.74 fold); miR-602 (1.57 fold); miR-455-5p (2.01 fold); miR-205 (6.29 fold); miR-183* (1.8 fold); miR-425 (1.66 fold); miR-375 (1.72 fold); miR-193b (1.58 fold); miR-30e* (1.32 fold); miR-95 (378 fold); miR-378 (1.65 fold); miR-455-3p (2.12 fold); miR-133a (2.19 fold); miR-873 (2.3 fold); miR-222 (2.17 fold); miR-21 (1.71 fold); miR-142 -3p (1.65 fold); miR-575 (1.7 fold) ;miR-130b (1.62 fold); miR-339-3p (1.19 fold); miR-149 (1.82 fold); miR-338-3p (1.96 fold); miR-19a (1.4 fold); miR-148a (1.63 fold); miR-146b-5p (1.68 fold); miR-125a-5p (1.41 fold); miR-27b (1.27 fold); miR-10b* (1.94 fold); miR-141 (1.42 fold); miR-7 (1.76 fold); miR-505 (1.33 fold); miR-30c-1* (1.41 fold); miR-145* (2.01 fold); miR-145 (2.01 fold); miR-125b (1.37 fold); miR-99a (1.34 fold); miR-378* (1.97 fold); miR-583 (1.82 fold); miR-221* (2.1 fold); miR-20a (1.4 fold); miR-124 (1.67 fold); miR-103 (1.21 fold); miR-542-5p (1.77 fold); miR-193b* (1.68 fold); miR-941 (1.52 fold)] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(miR-96):- synapse; generation of neurons; neurogenesis; cell part morphogenesis; cell projection morphogenesis Pathways Include(miR-142-3p):- DNA-binding transcription factor activity, RNA polymerase II-specific; nuclear chromatin; DNA binding; chromatin; Cellular Component nuclear chromosome Pathways Include(miR-148a):- MicroRNAs in cancer; neuron projection; nervous system development; axon; synapse |
| Experiment | Prostate Cancer (PCa)Vs Normal Adjacent Prostate (NAP) |
| Type of Biomarker | Diagnostic |
| Cohort | Validation Set: All 24 paired NAP and PCa samples were chosen for validation. |
| Senstivity | 100% |
| Specificity | 66.7% |
| AUC | 0.875 |
| Accuracy | NA |
| Level Of Significance | p= 0.0046 |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Cohort |
| Technical Name | miR-96, miR-182, miR-32, miR-221, miR-25, miR-93, miR-182*, miR-106b, miR-183, miR-153, miR-602, miR-455-5p, miR-205 miR-183*, miR-425, miR-375, miR-193b, miR-30e*, miR-95, miR-378, miR-455-3p, miR-133a, miR-873, miR-222, miR-21, miR-142-3p, miR-575, miR-130b, miR-339-3p, miR-149, miR-338-3p, miR-19a, miR-148a, miR-146b-5p, miR-125a-5p, miR-27b, miR-10b*, miR-141, miR-7, miR-505, miR-30c-1*, miR-145*, miR-145, miR-125b, miR-99a, miR-378*, miR-583, miR-221*, miR-20a, miR-124, miR-103, miR-542-5p, miR-193b*, miR-941 |